garen olog 112					
Revision:	HCFA-PM-92-2 MARCH 1992	74 (MB)			
	State/Territory:	Missouri			
Citation 1927(g)	4.26	Drug Utilization Review Program The Medicaid agency meets the requirements of Section 1927(g) of the Act for a drug use review (DUR) program for outpatient drug claims.			
1927(g)(1) (A) <u>X</u>	The DUR program assures that prescriptions for outpatient drugs are:			
	<u> x</u>	AppropriateMedically necessaryDre not likely to result in adverse medical results Identify and The DUR program is designed to educate physicians and pharmacistato reduce the frequency of patterns of fraud, abuse, gross overuse, or inappropriate or medically unnecessary care among physicians, pharmacist, and patients or associated with specific drugs, as well as:			
		Potential and actual adverse drug reactionsTherapeutic appropriatenessOverutilization and underutilizationAppropriate use of generic products*Therapeutic duplicationDrug disease contraindicationsDrug interactionsIncorrect drug dosage or durationDrug allergy interactionsClinical abuse/misuse			
1927(g)(1)(B) <u>X</u>	The DUR program shall assess data against predetermined standards consistent with:			
		The peer reviewed medical literature Three compendia specified by the statute			
1927/01/1	\(D\) v	DUP is not required for drugg dignersed to			

1927(g)(1)(D) DUR is not required for drugs dispensed to residents of nursing facilities that are in compliance with drug regimen review procedures set forth in 42 CFR 483.60. DUR is required for drugs dispensed to residents of nursing facilities which are not in compliance with 42 CFR 483.60.

1927(g)(2)(A) X The DUR program includes prospective review of drug therapy at the point of sale before each prescription is filled or delivered to the Medicaid recipient.

* This is accomplished through a drug prior authorization process to allow trade name override when medically necessary.

TN No. Supersedes TN No. New Material Revision: HCFA-PM-92-2 MARCH 1992 State/Territory: Citation 1927(g)(2)(A)(i)

1927(q)(2)(B)

Missouri

(MB)

Prospective DUR includes screening for potential drug therapy problems due to:

--Therapeutic duplication

-- Drug disease contraindications

--Drug interactions

-- Incorrect dosage or duration

-- Drug allergy interactions *

--Clinical abuse/misuse

Prospective DUR includes counseling for Medicaid 1927(g)(2)(A)(ii) X recipients based on standards established by State law and maintenance of patient profiles.

> The DUR program includes retrospective DUR through Х its mechanized drug claims processing and information retrieval system or otherwise which undertakes ongoing periodic examination of claims data and other records to identify:

> > -- Patterns of fraud and abuse

--Gross overuse

-- Inappropriate or medically unnecessary care

Х The DUR program assesses data on drug use against 1927(g)(2)(C). explicit predetermined standards including but not limited to monitoring for:

-- Therapeutic appropriateness

--Overutilization and underutilization

--Appropriate use of generic products

-- Therapeutic duplication

-- Drug disease contraindications

--Drug interactions

-- Incorrect dosage/duration

--Clinical abuse/misuse

The DUR program through its State DUR Board, using Х 1927(g)(2)(D) data provided by the Board, provides for active and ongoing educational outreach programs to educate practitioners on common drug therapy problems to improve prescribing and dispensing practices.

The DUR program has established a State DUR Board 1927(g)(3)(A) _X_ either:

> Directly Contract with a private organization

* This is done by the pharmacy provider through profiling onsite not by the point-of-sale computer system.

TN No. 93-13 Supersedes TN No. New Material

Approval Date

AUG 3 0 1993

Effective Date April 1, 199

₹

				-
	Revision:	HCFA-PM-92- 2	74b	
	VeATPION:	1992 MARCH	(MB)	
•		State/Territory:	Missouri	
	Citation			
	1927 (g) (3)	(B) <u>/</u>	The DUR Board membership includes health professionals (one-third licensed actively practicing pharmacist and one-third but no more than 51 percent licensed and actively practicing physicians) with knowledge and experience in:	
•			 Clinically appropriate prescribing and dispensing of covered outpatient drugs. Monitoring of covered outpatient drugs. Drug use review, evaluation and intervention. Medical quality assurance. 	
	1927(g)(3)	(C)	The activities of the DUR Board include:	
			Retrospective DURApplication of StandardsOngoing interventions for physicians and pharmacists targeted toward therapy problems or individuals identified in the course of retrospective DURInterventions include in appropriate instances: -Information dissemination -Written, oral, and electronic remindersFace to Face discussions	3

An annual report is submitted to the Secretary, including a report from its DUR Board, on the DUR 1927(g)(3)(D) program.

-Intensified monitoring/review of

providers/dispensers

TN No. AUG 3 0 1993 Effective Date April 1, 1993 Supersedes Approval Date

TN No.